A molecule in the blood shows promise as a marker to predict whether individual rheumatoid arthritis patients are likely to benefit from biologic medications or other drugs should be tried. PubMed, Mayo Clinic News Network, 11/17/2014. (Also see: Treatments for Rheumatoid Arthritis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.